Literature DB >> 3102830

Myoadenylate deaminase deficiency: successful symptomatic therapy by high dose oral administration of ribose.

N Zöllner, S Reiter, M Gross, D Pongratz, C D Reimers, K Gerbitz, I Paetzke, T Deufel, G Hübner.   

Abstract

A 55 years old patient suffering from exercise-induced muscle pain and stiffness due to primary myoadenylate deaminase deficiency has been successfully treated with D-ribose since 1984: single doses of 4 grams administered at the beginning of exercise prevented the symptoms completely; on continuation of exercise this dose had to be repeated all 10-30 min. Total doses of 50-60 g per day were tolerated without side-effects.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3102830     DOI: 10.1007/bf01785710

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  46 in total

1.  D-ribose inhibits DNA repair synthesis in human lymphocytes.

Authors:  G Zunica; M Marini; M A Brunelli; M Chiricolo; C Franceschi
Journal:  Biochem Biophys Res Commun       Date:  1986-07-31       Impact factor: 3.575

2.  AMP deaminase reaction as a control system of glycolysis in yeast. Role of ammonium ion in the interaction of phosphofructokinase and pyruvate kinase activity with the adenylate energy charge.

Authors:  M Yoshino; K Murakami
Journal:  J Biol Chem       Date:  1985-04-25       Impact factor: 5.157

3.  [Xylitol balance during long-term infusions with constant amounts in healthy men].

Authors:  P U Heuckenkamp; N Zöllner
Journal:  Klin Wochenschr       Date:  1972-11-15

4.  A standardized forearm ischemic exercise test.

Authors:  T L Munsat
Journal:  Neurology       Date:  1970-12       Impact factor: 9.910

5.  Sensitive assay of carnitine palmitoyl transferase activity in tissue homogenates with a modified spectrophotometric method for enzymatic carnitine determination.

Authors:  T Deufel; O H Wieland
Journal:  Clin Chim Acta       Date:  1983-12-15       Impact factor: 3.786

6.  Ribose tolerance in gouty patients.

Authors:  M Pizzichini; R Marcolongo; E Marinello
Journal:  Adv Exp Med Biol       Date:  1980       Impact factor: 2.622

7.  Metabolism of D-ribose administered continuously to healthy persons and to patients with myoadenylate deaminase deficiency.

Authors:  M Gross; S Reiter; N Zöllner
Journal:  Klin Wochenschr       Date:  1989-12-04

8.  Exercising muscle does not produce hypoxanthine in adenylate deaminase deficiency.

Authors:  V H Patterson; K K Kaiser; M H Brooke
Journal:  Neurology       Date:  1983-06       Impact factor: 9.910

9.  alpha-Fucose inhibits human mixed-lymphocyte culture reactions and subsequent suppressor cell generation.

Authors:  J Stankova; M Rola-Pleszczynski
Journal:  Cell Immunol       Date:  1984-01       Impact factor: 4.868

10.  Skeletal muscle adenosine, inosine and hypoxanthine release following ischaemic forearm exercise in myoadenylate deaminase deficiency and McArdle's disease.

Authors:  S Sinkeler; E Joosten; R Wevers; R Binkhorst; L Oei
Journal:  Adv Exp Med Biol       Date:  1986       Impact factor: 2.622

View more
  19 in total

1.  Muscle metabolism and red cell ATP/ADP concentration during bicycle ergometer in patients with AMPD-deficiency.

Authors:  D R Wagner; J Felbel; U Gresser; N Zöllner
Journal:  Klin Wochenschr       Date:  1991-04-04

2.  Type 2a fibre rhabdomyolysis in myoadenylate deaminase deficiency.

Authors:  C Zimmer; H Altenkirch; S Dorfmüller-Küchlin; D Pongratz; I Paetzke; G Gosztonyi
Journal:  J Neurol       Date:  1991-02       Impact factor: 4.849

3.  McArdle's disease: successful symptomatic therapy by high dose oral administration of ribose.

Authors:  D R Wagner; N Zöllner
Journal:  Klin Wochenschr       Date:  1991-01-22

4.  Metabolism of D-ribose administered continuously to healthy persons and to patients with myoadenylate deaminase deficiency.

Authors:  M Gross; S Reiter; N Zöllner
Journal:  Klin Wochenschr       Date:  1989-12-04

Review 5.  Molecular biology of AMP deaminase deficiency.

Authors:  M Gross
Journal:  Pharm World Sci       Date:  1994-04-15

6.  Effects of therapeutic ribose levels on human lymphocyte proliferation in vitro.

Authors:  W Pliml; T von Arnim; C Hammer
Journal:  Clin Investig       Date:  1993-10

7.  The oxidative pentose phosphate pathway in the heart: regulation, physiological significance, and clinical implications.

Authors:  H G Zimmer
Journal:  Basic Res Cardiol       Date:  1992 Jul-Aug       Impact factor: 17.165

8.  Myoadenylate deaminase deficiency with severe rhabdomyolysis.

Authors:  F A Baumeister; M Gross; D R Wagner; D Pongratz; R Eife
Journal:  Eur J Pediatr       Date:  1993-06       Impact factor: 3.183

9.  Serum levels of glucose, insulin, and C-peptide during long-term D-ribose administration in man.

Authors:  M Gross; N Zöllner
Journal:  Klin Wochenschr       Date:  1991-01-04

10.  Ergometer exercise in myoadenylate deaminase deficient patients.

Authors:  M Gross; U Gresser
Journal:  Clin Investig       Date:  1993-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.